Nadir Platelet Counts Tied to AKI in Pediatric Open-Heart Surgery

Share this content:
Nadir Platelet Counts Tied to AKI in Pediatric Open-Heart Surgery
Nadir Platelet Counts Tied to AKI in Pediatric Open-Heart Surgery

MONDAY, Jan. 23, 2017 (HealthDay News) -- For pediatric patients undergoing cardiopulmonary bypass (CPB), postoperative nadir platelet counts are associated with the severity of acute kidney injury (AKI), according to a review published online Jan. 18 in Pediatric Anesthesia.

Shannon Tew, M.D., from Camelback Anesthesiology Consultants in Tempe, Ariz., and colleagues conducted a retrospective review of medical records and database for a single institution over a five-year period for 814 patients younger than 21 years undergoing cardiac surgery with CPB. They captured demographics, laboratory, and surgical characteristics, and recorded clinical event rates.

The researchers observed a 48 percent decrease in postoperative platelet counts from baseline, reaching a mean nadir value of 150 × 109 L−1 on postoperative day three. Thirty-seven percent of patients had AKI, including 13, 17, and 6 percent, respectively, with Acute Kidney Injury Network stages 1, 2, and 3. There was a correlation for the magnitude of nadir platelet counts and the severity of AKI. Nadir platelet counts, CPB time, Aristotle score, patient weight, intraoperative packed red blood cell transfusion, and having a heart transplant procedure were independent predictors of AKI severity.

"In pediatric open-heart surgery, thrombocytopenia and AKI occur commonly following CPB," the authors write. "Our findings show a strong association between nadir platelet counts and the severity of AKI."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »